Administrative Core

行政核心

基本信息

批准号：
10688372
负责人：
FRED R HIRSCH
金额：
$ 45.88万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10688372
关键词：
2019-nCoV Adherence Administrator Advocate Age Antibodies Antibody Response Area Basic Science Budgets COVID-19 COVID-19 susceptibility Cancer Center Cancer Patient Caregivers Clinical Clinical Research Collaborations Colorado Communication Complex Consult Data Science Core Doctor of Medicine Doctor of Philosophy Ensure Epidemiology Ethnic Origin Expenditure Foundations Gender Health system Hearing Infection Institutes Institution Interdisciplinary Study International Laboratories Leadership Lung Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of thorax Medical Monitor National Cancer Institute Office of Administrative Management Patient Monitoring Patient Recruitments Patient advocacy Patients Preparation Preventive measure Principal Investigator Progress Reports Publications Reporting Research Research Activity Research Personnel Resource Sharing Resources SARS-CoV-2 antibody SARS-CoV-2 infection Science Serology Services Socioeconomic Status Texas Thoracic Oncology TimeLine Travel Universities Vaccination Vaccines Videoconferencing Voice Work advocacy organizations anticancer research base cohort data sharing design distinguished professor experience human subject individual responsibility inter-institutional medical schools meetings professor programs recruit symposium synergism translational cancer research translational research program vaccinology virology

项目摘要

ADMINISTRATIVE CORE: ABSTRACT Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main interface with patient advocates, NCI program staff, external and internal advisory boards, NCI SeroNet activities, other Lung Cancer NCI Networks, and collaborating institutions. The Center’s Administrative Core is led by three world leaders in lung cancer translational research, founders of the COVID-19 Lung Cancer Consortium (CLCC), who all have extensive experience leading large and complex lung cancer translational research programs: Dr. Fred R. Hirsch at the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, Dr. John Minna at UTSW and Dr. Paul A. Bunn Jr. at the University of Colorado. The Administration Core PIs will work closely with the U54 overall Co-PI (Dr. Adolfo Garcia-Sastre), the U54’s Steering Committee, which consists of the overall PIs, the Administrative Core PIs, the Project and Core PIs, and a representative for our partner organization, the patient advocacy organization GO2 Foundation for Lung Cancer. The U54’s Steering Committee will have the assistance and advice of an Internal Advisory Board (IAB) and an External Advisory Board (EAB). The IAB will be established within the Mount Sinai Health System and will provide scientific advice and smooth access to required institutional resources. The EAB consists of international leaders in thoracic oncology and in medical virology and vaccinology and will assist with providing scientific advice and evaluating scientific progress with a special focus on lung cancer implications. The specific aims of the Administrative Core are: AIM 1: Direct the overall scientific integration and administrative management of the U54 and ensure effective communication between U54 Project and Core investigators; AIM 2: Oversee Administration of Patient Cohorts, Clinical Studies, Financial Reporting, and Regulatory Aspects; and AIM 3: Manage connection of the U54 with the NCI, SeroNet, and other lung cancer research (e.g. NCI Lung-SPORE) and patient advocacy networks. Thus, the Administrative Core will help this U54 to maximize its potential both internally (Mount Sinai, UTSW, and University of Colorado), and inter-institutionally, including interactions with the NCI Serological Sciences Network and the Frederick National Laboratory for Cancer Research (FNLCR). Successful completion of our U54 activities is expected to substantially increase our understanding of the association between lung cancer SARS-CoV-2 antibody response based on infection or vaccination, and ultimately be of significant service in designing lung cancer patient-specific SARS-CoV-2 preventive measures.

行政核心：摘要我们的跨机构 U54 血清学科学卓越中心 (“U54”) 行政核心为 U54 的所有项目和核心提供科学和行政监督。与患者倡导者、NCI 项目工作人员、外部和内部顾问委员会、NCI SeroNet 活动、其他肺癌 NCI 网络和合作机构该中心的行政核心由三个领导。肺癌转化研究领域的世界领导者、COVID-19 肺癌联盟 (CLCC) 的创始人、他们都拥有领导大型复杂肺癌转化研究项目的丰富经验： Fred R. Hirsch，蒂施癌症研究所和西奈山伊坎医学院，John Minna 博士， UTSW 和科罗拉多大学的 Paul A. Bunn Jr. 博士将与管理核心 PI 密切合作。 U54 总体 Co-PI（阿道夫·加西亚-萨斯特雷博士），U54 的指导委员会，由总体组成 PI、管理核心 PI、项目和核心 PI 以及我们合作伙伴组织的代表患者权益倡导组织 GO2 肺癌基金会将设立 U54 指导委员会。内部顾问委员会 (IAB) 和外部顾问委员会 (EAB) 的协助和建议。将在西奈山卫生系统内建立，并将提供科学建议和顺利获得服务 EAB 由胸部肿瘤学和医学领域的国际领导者组成。病毒学和疫苗学，并将协助提供科学建议并评估科学进展特别关注肺癌的影响行政核心的具体目标是： AIM 1：直接。 U54整体科学整合和行政管理，确保有效沟通 U54 项目和核心研究人员之间；目标 2：监督患者队列的管理、临床研究、财务报告和监管方面；以及 AIM 3：管理 U54 与 NCI、SeroNet、以及其他肺癌研究（例如 NCI Lung-SPORE）和患者倡导网络。行政核心将帮助这支 U54 在内部（西奈山、UTSW 和科罗拉多大学），以及机构间，包括与 NCI 血清学科学网络的互动和弗雷德里克国家癌症研究实验室 (FNLCR)。成功完成我们的 U54 活动预计将大大增加我们对基于感染或疫苗接种的肺癌 SARS-CoV-2 抗体反应之间的关联，以及最终对于设计针对肺癌患者的 SARS-CoV-2 预防措施具有重要意义。